)
Edge23 Jan 2026
Death, Taxes, and Garbage: The Story of WM
How Waste Management turned garbage into one of America's most stable business models through landfills, regulation, and nationwide scale.
Immuneering
Immuneering (IMRX) investor relations material
Immuneering Study Result summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Study Result summary7 Jan, 2026
12-month overall survival and efficacy results
12-month overall survival reached 64% for first-line pancreatic cancer patients treated with atebumetanib plus chemotherapy, nearly double the 35% benchmark from standard of care, with median overall survival not yet reached at a median follow-up of 13.4 months.
Median progression-free survival was 8.5 months versus 5.5 months for standard of care; overall response rate was 39% (vs. 23%), and disease control rate was 81% (vs. 48%).
Consistent survival benefit observed over time: 27-point separation at 6 months, 36-point at 9 months, and 29-point at 12 months compared to standard of care.
Expanded cohort of over 50 patients is showing survival trends consistent with the original 34-patient cohort, with updated data to be reported in the first half of 2026.
The study population was older (median age 69), with over two-thirds above 65, reinforcing the significance of the results.
Safety, tolerability, and quality of life
Atebumetanib plus chemotherapy demonstrated a favorable safety profile, with only anemia and neutropenia as Grade 3 adverse events in over 10% of patients; no new safety signals identified.
Grade 3 neutropenia and anemia each occurred in 18% of patients, lower or comparable to rates in pivotal studies of other regimens.
No Grade 5 events were reported in the study cohort.
Patients experienced meaningful improvements in quality of life, including weight gain, improved appetite, and increased independence, as highlighted in a case study.
Quality of life metrics will be included as secondary endpoints in the upcoming Phase 3 trial.
Next steps and future plans
A pivotal global Phase 3 trial (MapKeeper 301) will enroll approximately 510 patients, comparing atebumetanib plus chemotherapy to standard of care, with overall survival as the primary endpoint; first patient dosing expected mid-year and top-line results anticipated in mid-2028.
Additional data from the expanded cohort and circulating tumor DNA analyses will be reported in the first half of the year.
Phase 2 combination studies in non-small cell lung cancer are planned to start in 2026, including combinations with Libtayo.
The company is well-funded with a cash runway into 2029, supporting ongoing and future studies.
Phase III control arm median OS assumption?
Ideal atebemetinib patient population profile?
Impact of subsequent therapies on OS data?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Immuneering earnings date
Q4 20252 Mar, 2026
Immuneering
Next Immuneering earnings date
Q4 20252 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Immuneering Corporation is a clinical-stage oncology company focused on developing novel therapeutics for cancer patients. The company leverages bioinformatics and computational biology to design drugs that cyclically disrupt core oncogenic signaling pathways, such as the MAPK pathway, with the aim of reducing tumor growth while minimizing toxicity. Immuneering’s pipeline includes its lead product candidate, IMM-1-104, a dual-MEK inhibitor in clinical trials targeting cancers caused by mutations in RAS and/or RAF. Another notable candidate is IMM-6-415, also targeting solid tumors. The company emphasizes a disease-agnostic approach, aiming to address cancers with high unmet medical needs through insights derived from its translational bioinformatics platform. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage